Castle Biosciences Inc (CSTL)vsDanaher Corporation (DHR)
CSTL
Castle Biosciences Inc
$32.03
+5.12%
HEALTHCARE · Cap: $928.40M
DHR
Danaher Corporation
$204.76
+2.39%
HEALTHCARE · Cap: $125.93B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 6927% more annual revenue ($25.11B vs $357.28M). DHR leads profitability with a 16.0% profit margin vs -5.4%. DHR earns a higher WallStSmart Score of 66/100 (B-).
CSTL
Hold37
out of 100
Grade: F
DHR
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+59.2%
Fair Value
$79.18
Current Price
$32.03
$47.15 discount
Margin of Safety
-66.7%
Fair Value
$117.88
Current Price
$204.76
$86.88 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Revenue surging 20.1% year-over-year
Earnings expanding 59.7% YoY
Large-cap with strong market position
Reasonable price relative to book value
Generating 1.3B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -2.8% — below average capital efficiency
Earnings declined 51.6%
Premium valuation, high expectations priced in
ROE of 7.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CSTL
The strongest argument for CSTL centers on Debt/Equity, Altman Z-Score, Price/Book. Revenue growth of 20.1% demonstrates continued momentum.
Bull Case : DHR
The strongest argument for DHR centers on EPS Growth, Market Cap, Price/Book. Profitability is solid with margins at 16.0% and operating margin at 18.0%. PEG of 1.15 suggests the stock is reasonably priced for its growth.
Bear Case : CSTL
The primary concerns for CSTL are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Return on Equity.
Key Dynamics to Monitor
CSTL profiles as a growth stock while DHR is a mature play — different risk/reward profiles.
CSTL carries more volatility with a beta of 0.97 — expect wider price swings.
CSTL is growing revenue faster at 20.1% — sustainability is the question.
DHR generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
DHR scores higher overall (66/100 vs 37/100), backed by strong 16.0% margins. CSTL offers better value entry with a 59.2% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Castle Biosciences Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Castle Biosciences Inc. is a pioneering diagnostics firm that enhances patient care through advanced gene-expression profiling tests, particularly within the skin cancer sector, exemplified by its flagship product, DecisionDx®-Melanoma. This innovative test offers essential insights for risk stratification, enabling oncologists to make informed treatment decisions in managing melanoma. With a strong focus on precision medicine, coupled with an extensive research and development strategy, Castle Biosciences is poised for growth as it seeks to expand its offerings and meet critical clinical demands. By addressing the complexities inherent in oncology, the company not only aims to improve patient outcomes but also to generate substantial value for its investors.
Visit Website →Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?